Évolution naturelle des lymphocytoses B monoclonales
Réf. : HematoStat.net ; 2 (2) : R16 Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families Slager, S. L. and al. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood 137, 2046–2056 (2021). Résumé : Il est [...]
Ixazomib, daratumumab et dexaméthasone en 1re ligne pour les patients fragiles
Réf. : HematoStat.net ; 2 (2) : R15 Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study Stege, C. A. M. and al. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple [...]
Autogreffe vs allogreffe dans le lymphome T périphérique
Réf. : HematoStat.net ; 2 (2) : R14 A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL Schmitz, N. and al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part [...]
Traitement ciblé dans la leucémie à tricholeucocytes en rechute
Réf. : HematoStat.net ; 2 (2) : R13 Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia Tiacci, E. and al. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N. Engl. J. Med. 384, 1810–1823 (2021). Résumé : La leucémie à [...]
Traitement de maintenance par azacytidine orale dans les LAM
Réf. : HematoStat.net ; 2 (1) : R12 Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission Wei, A. H. et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N. Engl. J. Med. 383, 2526–2537 (2020). Résumé [...]
APR-246 et azacytidine dans les SMD avec mutation de TP53
Réf. : HematoStat.net ; 2(1) : R11 Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes Sallman, D. A. et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J. Clin. Oncol. JCO.20.02341 (2021) doi:10.1200/JCO.20.02341. Résumé : L’APR-246 est une molécule orale qui permet [...]
Inhibition de Bcl-2 dans le lymphome B diffus à grandes cellules
Réf. : HematoStat.net ; 2(1) : R10 phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma Morschhauser, F. et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse [...]
Une seconde administration de CAR T en cas d’échec ?
Réf. : HematoStat.net ; 2 (1) : R9 Factors associated with outcomes after a second CD19-targeted CAR T-cell 2 infusion for refractory B cell malignancies Gauthier, J. and al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell [...]
Inhibition de la DP-4 et prévention de la GVH aiguë
Réf. : HematoStat.net ; 2 (1) : R8 Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease Farag, S. S. et al. Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease. N. Engl. J. Med. 384, 11–19 (2021). Résumé : Les [...]
Traitements par inhibiteurs de PARP et risque de SMD
Réf. : HematoStat.net ; 2 (1) : R7 Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database Morice, P.-M. and al. Myelodysplastic syndrome and [...]
English 
French 